Dr Marie-Elise TruchetetRhumatologue à Bordeaux

2026Rheumatology (Oxford, England)PubMed

Effectiveness of oral anticoagulants in precapillary pulmonary hypertension associated with systemic sclerosis: a EUSTAR cohort study

2026Annals of the rheumatic diseasesPubMed

Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design

2026Arthritis & rheumatology (Hoboken, N.J.)PubMed

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

2026Annals of the rheumatic diseasesPubMed

High-throughput plasma proteomics reveals circulating biomarkers of interstitial lung disease and progressive pulmonary fibrosis in systemic sclerosis

2026Arthritis care & researchPubMed

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort

2026RMD openPubMed

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study

2026Rheumatology (Oxford, England)PubMed

Clinical characteristics and risk factors for calcinosis cutis in systemic sclerosis: insights from the EUSTAR database

2026Therapeutic advances in musculoskeletal diseasePubMed

The clinical phenotype of anti-Th/To+ patients in systemic sclerosis: a case-control study within the European Scleroderma Trials and Research cohort

2026Microvascular researchPubMed

Nailfold video capillaroscopy predicts severe progression at three years in systemic sclerosis: Results from SCLEROCAP study

2026Current opinion in rheumatologyPubMed

What have we learned about systemic sclerosis from the EUSTAR database?

2025The Lancet. RheumatologyPubMed

Exploiting a unified vascular framework to predict organ-specific complications and accomplish disease modification in systemic sclerosis

2025Rheumatology (Oxford, England)PubMed

Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort

2025Rheumatology (Oxford, England)PubMed

Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort

2025Journal of scleroderma and related disordersPubMed

Longitudinal association between nailfold capillaroscopy and incident interstitial lung disease: A EUSTAR database analysis

2025NPJ digital medicinePubMed

Deep hierarchical subtyping of multi-organ systemic sclerosis trajectories - a EUSTAR study

2025Arthritis care & researchPubMed

Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database

2025Arthritis research & therapyPubMed

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort

2025Journal of the American Heart AssociationPubMed

Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort

2025The Journal of experimental medicinePubMed

Altered X-chromosome inactivation of the TLR7/8 locus and heterogeneity of pDCs in systemic sclerosis

2025Journal of autoimmunityPubMed

Total lung capacity is predictive of disease severity and survival in systemic sclerosis: A longitudinal analysis in 2347 patients from the French National Cohort Study

2024Rheumatology (Oxford, England)PubMed

Occupational quantitative exposure to crystalline silica, solvents and pesticides and risk of clinical forms of systemic sclerosis

2024Rheumatology (Oxford, England)PubMed

Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis

2024Arthritis research & therapyPubMed

Does regression of skin thickening predict improvement of internal organ involvement and survival in patients with diffuse cutaneous systemic sclerosis? A EUSTAR analysis

2024RMD openPubMed

Comorbidity burden on mortality in patients with systemic sclerosis

2024ChestPubMed

Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis

2024European journal of immunologyPubMed

The deficiency of DNASE1L3 does not affect systemic sclerosis pathogenesis in two inducible murine models of the disease

2026Rheumatology (Oxford, England)PubMed

Proton pump inhibitor use and long-term outcomes in SSc: a real-life analysis from the EUSTAR database

2026Annals of the rheumatic diseasesPubMed

Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST score

2026BMC women's healthPubMed

Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study

2025La Revue de medecine internePubMed

[Between the normal and the pathological: The concept of pre-disease applied to systemic autoimmune rheumatic diseases]

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

2026Joint bone spinePubMed

Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry

2025BMJ openPubMed

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

2025Rheumatology (Oxford, England)PubMed

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

2026RMD openPubMed

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

2025BMJ openPubMed

Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial

2025Annals of the rheumatic diseasesPubMed

Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

2026Arthritis care & researchPubMed

Real-World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched Study From the EUSTAR Cohort

2026Joint bone spinePubMed

Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry

2025RMD openPubMed

Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study

2026Joint bone spinePubMed

Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update

2025Joint bone spinePubMed

French recommendations for assessing and managing the risk of cancer before the initiation of targeted therapies for chronic rheumatic inflammatory diseases

2026Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseasesPubMed

Adherence to Biologics and Psycho-cognitive Factors in Axial Spondyloarthritis: A Multicentric Cross-sectional Study

2024Joint bone spinePubMed

Standardized reporting for systematic global evaluation of axial spondyloarthritis: An evidence-based and consensus-driven initiative

2025Rheumatology (Oxford, England)PubMed

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

2024Annals of the rheumatic diseasesPubMed

EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease

2024RMD openPubMed

Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients

2026European journal of internal medicinePubMed

European practices for screening and follow-up in mixed connective tissue disease: a survey of clinicians from the European Federation of Internal Medicine and ERN ReCONNET

2025Arthritis research & therapyPubMed

The effect of hydroxychloroquine on activities of daily living and hand function in systemic sclerosis: results from an analysis of the EUSTAR cohort

2026BMC rheumatologyPubMed

Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study

2025Orphanet journal of rare diseasesPubMed

Prevalence estimation of a rare disease with the French National Rare Disease Registry: example of TNF receptor associated periodic syndrome (TRAPS)

2025Arthritis & rheumatology (Hoboken, N.J.)PubMed

Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica

2025Autoimmunity reviewsPubMed

Crystalline silica on the lung-environment interface: Impact on immunity, epithelial cells, and therapeutic perspectives for autoimmunity

2026Joint bone spinePubMed

Cardiovascular risk assessment using the DAS28-GGT score in rheumatoid arthritis patients initiating JAK inhibitors: Results from the MAJIK-SFR registry

2012 · Bordeaux 2

Etude de l’implication de l’axe IL-23/Th17 dans deux modèles physiopathologiques humains : la réponse à Mycoplasma hominis et la sclérodermie systémique

2025 · doctorant : Stefano Di donato

A reverse clinical translation platform for the molecular stratification of vascular progression in Systemic Sclerosis (SSc)

2021 · doctorant : Damien Leleu

Propriétés immunologiques et non immunologiques des microparticules au cours de la sclérodermie systémique